Under mounting pressure from the Food and Drug Administration (FDA), Bayer Corporation suspended the sale of its hugely profitable drug Trasylol in November 2007.

Trasylol, a blood-clotting drug used during heart surgery to control bleeding, has been administered to more than 4.5 million people worldwide. About 1.5 million Americans received Trasylol during its 14 years on the US market.

The studies found that patients who received Trasylol during heart bypass, heart valve replacement, and other heart surgeries were more likely to die than patients who received other available blood-clotting medications. The deaths were due to heart failure, kidney failure, heart attacks and strokes that the patients suffered after surgery.

In 2007, Bayer designed a major Canadian trial to show that Trasylol was better than other medications for controlling bleeding. However, the trial was canceled due to an increase in deaths among heart surgery patients using the drug. Patients who received Trasylol had a 50 percent increased risk of dying compared to patients who received other medications.

What are a few thousand deaths among friends?

60 minutes reported in February 2008 that Bayer had known about Trasylol’s safety concerns for decades and about abnormally high incidents of deaths associated with the drug since 2006. However, Bayer continued to aggressively market the drug, raising more than $300 million annually. . The FDA allowed Trasylol to remain on the market, contributing to about 1,000 deaths per month in the 22 months prior to its recall.

Tea 60 minutes The report went on to describe Bayer’s own internal study evaluating the risk of death of patients from Trasylol. The medical records of nearly 70,000 patients were examined by a Harvard professor who was placed on Bayer’s payroll. What the professor found was that patients who received Trasylol had an elevated risk of acute kidney failure.

Bayer hid this study from the FDA during a safety review of Trasylol in 2006. The pharmaceutical giant further enticed the FDA into allowing Trasylol to remain on the market. It was more than a year before the FDA re-reviewed Trasylol’s side effects. Ultimately, the FDA withdrew the drug but imposed no fines or penalties on Bayer.

What does this have to do with fleas and ticks on dogs and cats?

Another way Bayer works wonders is with its insecticide Imidacloprid, the active ingredient in Advantage Flea and Tick Treatment for dogs and cats. Laboratory test results on file with the US Environmental Protection Agency show that imidicloprid is neurotoxic to dogs and other laboratory animals, and also causes impaired coordination, labored breathing, reduced birth weight, increased birth defects, and thyroid injury.

Of course, Bayer has been silent as a stalactite about these adverse health effects on our precious pets. could this be another 60 minutes report in progress?

Sooner or later, responsible dog lovers and cat lovers alike must ask themselves the question: Am I trusting big pharmaceutical companies too much with the safety of my best friends? Sooner or later, you have to wonder if toxic chemicals are really necessary when safe, natural flea and tick treatments are available.

What is my advice? You can’t ask questions too soon, but they can ask them too late. Find out now why pet lovers around the world turn to TripleSure natural flea and tick spray for dogs and cats.